Efficacy of Dupilumab for Induction and Maintenance of Remission in Patients With Eosinophilic Gastritis, Enteritis, and Colitis With Concomitant Eosinophilic Esophagitis
Neurogastroenterology & Motility · 2025-12 · 37 (12)
DOI: 10.1111/nmo.70177 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 18.10.2025. Verfasst von Pierfrancesco Visaggi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Enteritis, Eosinophilic Esophagitis, Gastritis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Eosinophilic gastrointestinal diseases (EGIDs) are chronic, immune‐mediated diseases characterized by pathological infiltration of eosinophils in the gut. EGIDs include eosinophilic esophagitis (EoE), gastritis (EoG), enteritis (EoN), and colitis (EoC). There are no approved drugs for non‐EoE EGIDs due to a lack of evidence. Aims and Methods In this case series, we report the efficacy of dupilumab—prescribed for concomitant EoE—for the induction and maintenance of remission of non‐EoE EGIDs. Adult patients (> 18 years) diagnosed with non‐EoE EGIDs and concomitant EoE who had been prescribed dupilumab 300 mg weekly were prospectively enrolled. Outcome assessment was performed according to EGID‐specific instruments when available (i.e., peak eosinophil count, modified dysphagia questionnaire, Pisa EoE adaptation questionnaire, EoE and EoG endoscopic reference scores).
Results
Four patients were included. All were female and their age spanned 21–77 years at diagnosis. Two patients had EoE + EoG (case 1 and 2), one EoE + EoG + EoN (case 3), and one EoE + EoN + EoC (case 4). EoG presented with epigastric pain, while EoN and EoC presented with abdominal pain and diarrhea. Cases 1 and 2 achieved clinical, endoscopic, and histological remission with induction corticosteroid treatment, while case 3 did not, and case 4 developed steroid‐related adverse events. When switched to dupilumab 300 mg weekly, cases 1, 2, and 3 achieved histological remission and sustained clinical remission up to 12–18 months from induction. In case 4, dupilumab achieved histologic remission and partial clinical response up to 16 months from induction.
Conclusion
Dupilumab, prescribed for EoE, may be effective for the management of concomitant non‐EoE EGIDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
- Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
ORCID-Profile: Pierfrancesco Visaggi, Nicola de Bortoli
Zitieren
APA
Visaggi, P., Bini, L., Castagnaro, E., Cairoli, G., Testi, F., Mitilini, M., Bellini, M., Savarino, E. V., & de Bortoli, N. (2025). Efficacy of Dupilumab for Induction and Maintenance of Remission in Patients With Eosinophilic Gastritis, Enteritis, and Colitis With Concomitant Eosinophilic Esophagitis. Neurogastroenterology & Motility, 37(12). https://doi.org/10.1111/nmo.70177
Vancouver
Visaggi P, Bini L, Castagnaro E, Cairoli G, Testi F, Mitilini M, et al. Efficacy of Dupilumab for Induction and Maintenance of Remission in Patients With Eosinophilic Gastritis, Enteritis, and Colitis With Concomitant Eosinophilic Esophagitis. Neurogastroenterology & Motility. 2025;37(12). doi:10.1111/nmo.70177
BibTeX
@article{Visaggi2025,
author = {Visaggi, Pierfrancesco and Bini, Lorenzo and Castagnaro, Ester and Cairoli, Gaia and Testi, Federico and Mitilini, Mauro and Bellini, Massimo and Savarino, Edoardo V and de Bortoli, Nicola},
title = {Efficacy of Dupilumab for Induction and Maintenance of Remission in Patients With Eosinophilic Gastritis, Enteritis, and Colitis With Concomitant Eosinophilic Esophagitis},
journal = {Neurogastroenterology & Motility},
year = {2025},
volume = {37},
number = {12},
doi = {10.1111/nmo.70177}
}
EUVIMED